Cargando…

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

BACKGROUND: The impact of the coronavirus disease 2019 (COVID-19) pandemic on well-being has the potential for serious negative consequences on work, home life, and patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate well-being in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banerjee, S., Lim, K.H.J., Murali, K., Kamposioras, K., Punie, K., Oing, C., O'Connor, M., Thorne, E., Devnani, B., Lambertini, M., Westphalen, C.B., Garrido, P., Amaral, T., Morgan, G., Haanen, J.B.A.G., Hardy, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900705/ https://www.ncbi.nlm.nih.gov/pubmed/33601295 http://dx.doi.org/10.1016/j.esmoop.2021.100058

Ejemplares similares

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
por: Lim, K.H.J., et al.
Publicado: (2021)

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
por: Lim, K.H.J., et al.
Publicado: (2021)

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
por: Lim, K.H.J., et al.
Publicado: (2021)

LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration
por: Banerjee, S., et al.
Publicado: (2020)

Response to the letter entitled ‘On finding acceptance’
por: Lim, K.H.J., et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network
por: Morgan, G., et al.
Publicado: (2021)

Nachwuchsförderung durch die European Society for Medical Oncology (ESMO): Erfahrungen aus dem ESMO Young Oncologist Committee (YOC)
por: Oing, Christoph, et al.
Publicado: (2020)

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
por: Curigliano, G., et al.
Publicado: (2020)

Young oncologists’ perspective on the role and future of the clinician-scientist in oncology
por: Lim, K.H.J., et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

1578P Clinical outcomes of patients with cancer who tested positive for COVID-19 hospitalised in a UK district general hospital
por: Amjad, A., et al.
Publicado: (2021)

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines
por: Crawford, G.B., et al.
Publicado: (2021)

COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022)

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
por: Berghoff, A.S., et al.
Publicado: (2021)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
por: Banerjee, Susana, et al.
Publicado: (2018)

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
por: Martin, P., et al.
Publicado: (2023)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
por: van Halteren, H.K., et al.
Publicado: (2022)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

ESMO pays tribute to Professor José Baselga
por: Peters, S., et al.
Publicado: (2021)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
por: Garrido, P., et al.
Publicado: (2021)

European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows
por: Passaro, Antonio, et al.
Publicado: (2020)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
por: Zielinski, Christoph C, et al.
Publicado: (2016)

1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)
por: Romano, E., et al.
Publicado: (2021)

ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMO DCs): education, research and programme development survey
por: Kreye, G., et al.
Publicado: (2022)

ESMO Open—Cancer Horizons and the future of oncology
por: Zielinski, Christoph C
Publicado: (2016)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oao1b59cm65hgldlft0a0n86no